US Oncology Reports Second Quarter Operati...( HOUSTON Aug. 6 /- U...),Health

HOUSTON, Aug. 6 /PRNewswire/ -- US Oncology, Inc. ("US Oncology" or "the Company"), one of the nation's largest cancer care services companies, reported revenue of $881.6 million, EBITDA of $39.9 million, Adjusted EBITDA of $62.7 million, net loss of $7.6 million and operating cash flow of $42.5 million for the three months ended June 30, 2009.

US Oncology Second Quarter Results

• Adjusted EBITDA for the second quarter of 2009 increased to $62.7 million from $57.4 million for the same period in 2008 due primarily to growth in our network of physicians, increases in patient volumes in medical oncology and radiation, coupled with lower general and administrative expenses, partially offset by a $3.8 million decrease due to reduced utilization of Erythropoiesis-Stimulating Agents ("ESAs").
• During the second quarter of 2009, total revenue increased by 6.3 percent compared to the same period in 2008 as we continue to grow patient volumes and our network of physicians. At June 30, 2009, 38 more physicians were affiliated under Comprehensive Strategic Alliance ("CSA") agreements to provide comprehensive practice management services than as of the same date in 2008. Also, during the second quarter of 2009, 10 net physicians joined under Targeted Physician Services relationships, which include one or more of our Oncology Pharmaceutical Services, Oncology Reimbursement Solutions, research, Innovent Oncology or iKnowMed offerings. As of June 30, 2009, there were 84 physicians with signed agreements to join our network within the next 90 to 120 days and three integrated cancer centers under construction expected to be operational in the second half of 2009.
  

President and Chief Executive Officer Bruce Broussard stated: "We continue to make progress on our objectives of improving operating performance in the short-term, wh
'/>"/>